News | June 07, 2022
MEI Pharma and Kyowa Kirin report new clinical data on Zandelisib
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The human serum-based system shows reduced interferences when testing for pyrogenicity in more complex drug products, such as in blood-derived therapeutics
A research group led by Ben-Gurion University of the Negev managed to produce an innovative microchip for creating sperm in a culture by using a microfluidic system.
Futnani has over two decades of experience in delivering growth and transformation that spans several therapeutic areas.
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Low-dose atropine has emerged as an effective approach to slow the progression of myopia in children
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Motrin Oral Suspension, 100 mg/5 mL, of McNeil Consumer Healthcare (McNeil)
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
Subscribe To Our Newsletter & Stay Updated
